Literature DB >> 8612625

Role of insulin-like growth factors in autocrine growth of human retinoblastoma Y79 cells.

M Giuliano1, R Vento, M Lauricella, G Calvaruso, M Carabillo, G Tesoriere.   

Abstract

In this study, we have demonstrated that human retinoblastoma Y79 cells produce insulin-like growth factors (IGFs) type I and type II and release them into the medium. We have also ascertained, by means of competitive studies and cross-linking procedure, that Y79 cells contain the type-I IGF receptor (IGF-IR). Furthermore, surface-bound IGF-I is internalised by the receptor, then degraded to amino acids. Insulin, IGF-I and IGF-II caused down-regulation of IGF-IR; the effect is concentration and time dependent. Scatchard analysis demonstrated that incubation with insulin markedly decreased the binding capacity measured for IGF-I while the apparent Kd value calculated for IGF-I binding was not significantly modified. IGF-I, IGF-II and insulin induced tyrosine phosphorylation of IGF-IR. Tyrosine phosphorylation of this receptor with, however, a less strong signal, was detectable even in cells cultured in serum-free medium without the addition of any exogenous growth factor. Similar results have been found concerning the tyrosine phosphorylation of insulin receptor substrate-1 (IRS 1). Tyrosine phosphorylation of both IGF-IR and IRS 1, either under basal conditions or after stimulation with growth factors, was strongly inhibited when alpha-IR3, a monoclonal antibody to IGF-IR, was added to the culture. IGF-I was capable of inducing Y79 cell proliferation and its effect was entirely inhibited by the addition of alpha-IR3. This antibody also markedly reduced the proliferation of Y79 cells cultured in serum-free medium not supplemented with stimulatory factors. Our results indicate that IGF-I and IGF-IR mediate an autocrine growth mechanism in Y79 cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612625     DOI: 10.1111/j.1432-1033.1996.00523.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.

Authors:  Vassiliki Poulaki; Constantine S Mitsiades; Antonia M Joussen; Alexandra Lappas; Bernd Kirchhof; Nicholas Mitsiades
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Differentiation of Y79 cells induced by prolonged exposure to insulin.

Authors:  R Vento; M Giuliano; M Lauricella; M Carabillò; H Main; E Gerbino; G Tesoriere
Journal:  Mol Cell Biochem       Date:  1997-05       Impact factor: 3.396

3.  Induction of programmed cell death in human retinoblastoma Y79 cells by C2-ceramide.

Authors:  R Vento; M Giuliano; M Lauricella; M Carabillò; D Di Liberto; G Tesoriere
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.396

Review 4.  The role of IGF-1R in pediatric malignancies.

Authors:  Su Young Kim; Jeffrey A Toretsky; Daniel Scher; Lee J Helman
Journal:  Oncologist       Date:  2009-01-06

5.  In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player.

Authors:  Riccardo Di Fiore; Rosa Drago-Ferrante; Antonella D'Anneo; Giuseppa Augello; Daniela Carlisi; Anna De Blasio; Michela Giuliano; Giovanni Tesoriere; Renza Vento
Journal:  Cancer Biol Ther       Date:  2013-08-12       Impact factor: 4.742

6.  Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells.

Authors:  Wei-Ting Hsiao; Ming-Dar Tsai; Guey-Mei Jow; Lu-Tai Tien; Yih-Jing Lee
Journal:  Mol Vis       Date:  2012-07-20       Impact factor: 2.367

7.  A decision process for drug discovery in retinoblastoma.

Authors:  María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  Invest New Drugs       Date:  2020-11-16       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.